Silence Therapeutics
Clinical-stage biotechnology company developing siRNA therapeutics. Uses a proprietary siRNA design platform and chemically modified, ligand-conjugated oligonucleotides to achieve targeted delivery to hepatocytes. Advances programs through preclinical candidate selection and early-phase clinical trials in cardiovascular, hematology and selected rare diseases. Maintains an intellectual property portfolio and engages external partners, patient groups and investors to support discovery, development and disclosure.
Industries
Nr. of Employees
medium (51-250)
Silence Therapeutics
London, England, United Kingdom, Europe
Products
Investigational siRNA therapeutics (clinical-stage programs)
Clinical-stage siRNA development programs designed to modulate disease-relevant genes and advance candidates through early-phase clinical evaluation for genetically mediated cardiovascular, hematologic and rare diseases.
Investigational siRNA therapeutics (clinical-stage programs)
Clinical-stage siRNA development programs designed to modulate disease-relevant genes and advance candidates through early-phase clinical evaluation for genetically mediated cardiovascular, hematologic and rare diseases.
Services
External partnering and collaboration
Scientific and development partnerships to access external research, accelerate discovery and develop therapeutic candidates; flexible transaction models and ongoing alliance management.
Patient education resources
Development and distribution of disease-specific educational materials, downloadable eBooks and videos to support patients, caregivers and advocacy groups.
External partnering and collaboration
Scientific and development partnerships to access external research, accelerate discovery and develop therapeutic candidates; flexible transaction models and ongoing alliance management.
Patient education resources
Development and distribution of disease-specific educational materials, downloadable eBooks and videos to support patients, caregivers and advocacy groups.
Expertise Areas
- RNA interference therapeutics development
- Oligonucleotide chemistry and conjugation
- Liver-targeted drug delivery
- Preclinical pharmacology and in vivo modeling
Key Technologies
- RNA interference (RNAi)
- siRNA sequence optimization and chemical modification
- Ligand-conjugated oligonucleotides
- Linker chemistry for bioconjugation